Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
06 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
05 févr. 2024 16h05 HE
|
HilleVax, Inc.
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Veteran ABC News Correspondent John Quiñones to Speak at The Immunization Partnership 2024 Annual Dinner
31 janv. 2024 08h55 HE
|
The Immunization Partnership
HOUSTON, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The Immunization Partnership (TIP), a statewide nonprofit committed to a healthy Texas, is proud to welcome San Antonio native and award-winning ABC...
Vaccine Contract Manufacturing Market Expected to Grow at a CAGR of 17.8% from 2024 to 2031
23 janv. 2024 04h09 HE
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Jan. 23, 2024 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Vaccine Contract Manufacturing Market - (By...
Author and Health Equity Leader Daniel E. Dawes, J.D., to Keynote Inaugural Health Summit
18 janv. 2024 07h00 HE
|
The Immunization Partnership
HOUSTON, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The Immunization Partnership (TIP), a statewide nonprofit committed to a healthy Texas, announced Daniel E. Dawes, J.D., as the keynote speaker for its...
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
18 janv. 2024 07h00 HE
|
HilleVax, Inc.
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
08 janv. 2024 07h00 HE
|
HilleVax, Inc.
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and...
Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix
07 janv. 2024 11h00 HE
|
Curevo Vaccine
-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including...
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 18h28 HE
|
HilleVax, Inc.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference
21 déc. 2023 08h00 HE
|
Curevo Vaccine
SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...